SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

remibetadex

RFL·Rafael Holdings, Inc.
MIXED
Drug Impact Rating7/10
Trial phase
Filed/PDUFA (NDA submitted)
Time to market
If the FDA accepts the NDA for filing, a standard review would take 10 months from filing acceptance, with a potential PDUFA date in late 2027. Priority review (if granted) could shorten this to 6-8 months. The FDA has 60 days from the October 28 submission to decide on filing acceptance.
Why 7/10
The next hard catalyst is the FDA's decision on whether to accept the NDA for filing, due within approximately 60 days (by late December 2026). Remibetadex is the company's lead late-stage asset and primary value driver, though Rafael Holdings also holds interests in other early-stage pharma and medical device companies. The Phase 3 primary endpoint miss creates significant approval risk, making this a high-concentration binary event.
Actionable Insight MIXED

The next catalyst is the FDA's filing decision within approximately 60 days (by late December 2026). If the NDA is accepted, a PDUFA target action date will be assigned. If rejected, the stock could face significant downside given the Phase 3 primary endpoint miss. Watch for any financing announcements given the $22.1M cash balance and ongoing burn rate.

Price Chart

Loading chart...

Executive Summary

Remibetadex (Trappsol Cyclo) is Rafael Holdings' lead asset for Niemann-Pick Disease Type C (NPC), an ultra-rare fatal genetic disorder. A New Drug Application was submitted to the FDA on October 28, 2026, just one day before today's report date. The submission follows a pivotal Phase 3 trial that missed its primary endpoint (p=0.19) but showed statistically significant benefit in a prespecified subgroup and an overall survival analysis. The FDA has 60 days to decide whether to accept the NDA for review. Two competing NPC drugs were already approved in September 2024, creating a crowded rare-disease market. With $22.1M in cash and a quarterly burn rate around $8.5M, the company faces both regulatory and financing risk.

How It Works

Remibetadex is a synthetic sugar ring molecule (a cyclodextrin) that acts like a cholesterol sponge. In Niemann-Pick Disease Type C, a defective protein (NPC1) cannot move cholesterol out of cells, causing toxic buildup. Remibetadex substitutes for this missing function: its hollow core traps cholesterol, allowing it to be transported out of cells and excreted from the body. It is administered intravenously every two weeks.

Trial Status

The pivotal Phase 3 TransportNPC study (CTD-TCNPC-301) enrolled 94 NPC patients aged 3-70 years, randomized 2:1 to remibetadex 2000 mg/kg IV every 2 weeks or placebo for 96 weeks. The primary endpoint (change in 4-domain NPC Clinical Severity Scale at Week 96) was not met (p=0.19). A prespecified subgroup of 78 patients on background miglustat/leucine showed a statistically significant 71% slowing of disease progression (p=0.046). An overall survival analysis in infantile-onset patients showed an 85% mortality risk reduction versus registry controls (p=0.044). Serious adverse events were higher with remibetadex (35.9%) versus placebo (16.7%).

The Two-Sided Case

▲ Bull Case5
Statistically significant benefit in the prespecified subgroup (p=0.046) covering ~83% of the trial population provides a regulatory path forward
Overall survival analysis showed 85% mortality risk reduction (p=0.044), a compelling efficacy signal in a fatal disease with no prior approved therapies until 2024
Orphan Drug, Fast Track and Rare Pediatric Disease designations provide regulatory incentives and potential Priority Review Voucher eligibility upon approval
Multiple institutional investors doubled their positions in Q2 2026 (Citadel, State Street, Jane Street, Susquehanna, Kahn Brothers), signaling sophisticated investor interest
NPC is an ultra-rare disease with high unmet need; even with two recently approved competitors, a differentiated IV therapy could capture meaningful market share
▼ Bear Case5
Phase 3 trial missed the primary endpoint in the overall population (p=0.19), a significant hurdle for FDA approval that may require additional trials
Two FDA-approved NPC therapies already exist (Miplyffa/arimoclomol and Aqneursa/levacetylleucine, both approved September 2024), creating a competitive landscape that did not exist when remibetadex trials began
Serious adverse events were more than double in the treatment arm (35.9%) versus placebo (16.7%), raising safety concerns
Cash position of $22.1M as of July 31, 2026 provides only ~2.5 quarters of runway at current burn rates, likely requiring dilutive financing before any potential commercialization
Stock trades near its 52-week low of $1.09, reflecting market skepticism after the Phase 3 miss and the NDA submission based on subgroup data

Upcoming Catalysts

  • FDA filing decision on the NDA within ~60 days (by late December 2026)
  • If accepted, assignment of a PDUFA target action date and potential Priority Review designation
  • Q4 FY2026 earnings report scheduled for November 2, 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Rafael Holdings, Inc. PRESS-RELEASE RFL ·Originating report

Sources · 13

Hover a chip for the title
1 drugs.com2 markets.businessinsider.com3 nnpdf.org4 rafaelholdings.irpass.com5 panabee.com6 neurologylive.com7 fda.gov8 sec.gov9 sec.gov10 panabee.com11 drugs.com12 fintel.io13 cyclotherapeutics.com